Is ADDXF or DIVO a better dividend investment in 2026?

ADDXF currently yields 202.02% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: ADDXF offers higher current income.

What is the dividend yield difference between ADDXF and DIVO?

ADDXF has a forward dividend yield of 202.02% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 195.53 percentage points.

Home › Compare › ADDXF vs DIVO

ADDXF vs DIVO: Dividend Comparison 2026

ADDXF yields 202.02% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ADDXF wins by $126.50M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ADDXF

● Live price

202.02%

Share price

$0.99

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$126.53M

Annual income

$64,106,411.82

Full ADDXF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — ADDXF vs DIVO

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ADDXF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ADDXF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ADDXF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF

Annual income on $10K today (after 15% tax)

$17,171.72/yr

After 10yr DRIP, annual income (after tax)

$54,490,450.05/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, ADDXF beats the other by $54,489,615.62/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + DIVO for your $10,000?

ADDXF: 50%DIVO: 50%

100% DIVO50/50100% ADDXF

Portfolio after 10yr

$63.28M

Annual income

$32,053,696.75/yr

Blended yield

50.65%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys

DIVO buys

No recent congressional trades found for ADDXF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricADDXFDIVO

Forward yield	202.02% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$126.53M ✓	$30.7K
Annual income after 10y	$64,106,411.82 ✓	$981.68
Total dividends collected	$119.31M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ADDXF vs DIVO ($10,000, DRIP)

Year	ADDXF Portfolio	ADDXF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$30,902	$20,202.02	$11,349	$649.42	+$19.6K → ADDXF
2	$91,409	$58,344.23	$12,833	$688.83	+$78.6K → ADDXF
3	$259,102	$161,293.94	$14,459	$727.90	+$244.6K → ADDXF
4	$704,521	$427,281.62	$16,238	$766.49	+$688.3K → ADDXF
5	$1,839,646	$1,085,809.10	$18,179	$804.47	+$1.82M → ADDXF
6	$4,618,204	$2,649,782.60	$20,293	$841.71	+$4.60M → ADDXF
7	$11,158,255	$6,216,776.60	$22,591	$878.14	+$11.14M → ADDXF
8	$25,977,314	$14,037,980.69	$25,087	$913.65	+$25.95M → ADDXF
9	$58,339,227	$30,543,501.04	$27,791	$948.18	+$58.31M → ADDXF
10	$126,529,384	$64,106,411.82	$30,718	$981.68	+$126.50M → ADDXF

ADDXF vs DIVO: Complete Analysis 2026

ADDXF — Stock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this ADDXF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHD ADDXF vs JEPI ADDXF vs O ADDXF vs KO ADDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.